| Market cap | $961.00M |
|---|---|
| Enterprise value | $722.53M |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$177.60 |
| Income | -$161.25 |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E | N/A |
|---|---|
| Forward P/E | -7.59 |
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| PEG | N/A |
| Price/Sales | N/A |
| P/FCF | N/A |
| Price/Book | 1.38 |
| Book/Share | 40.43 |
| Cash/Share | 40.89 |
| FCF yield | -13.38% |
| Volume | 53.176M / N/A |
|---|---|
| Relative vol. | N/A |
| EPS | N/A |
|---|---|
| EPS Q/Q | 13.04% |
| Est. EPS Q/Q | 50.00% |
| Profit margin | -29,192.90% |
|---|---|
| Oper. margin | N/A |
| Gross margin | 100.00% |
| EBIT margin | N/A |
| EBITDA margin | N/A |
| Ret. on assets | -22.26% |
|---|---|
| Ret. on equity | -22.93% |
| ROIC | -27.81% |
| ROCE | -24.18% |
| Debt/Equity | 0.04 |
|---|---|
| Net debt/EBITDA | 15.86 |
| Current ratio | 38.17 |
| Quick ratio | 38.17 |
| Volatility | 6.00% |
|---|---|
| Beta | 1.55 |
| RSI | 83.64 |
|---|
| Insider ownership | N/A |
|---|---|
| Inst. ownership | N/A |
| Shares outst. | 50.094M |
|---|---|
| Shares float | 0.000 0.00% |
| Short % of float | 17.77% |
| Short ratio | 10.45 |
| Dividend | N/A |
|---|---|
| Dividend yield | N/A |
| Payout ratio | N/A |
| Payment date | N/A |
| Ex-dividend date | N/A |
| Earnings date | 1 Aug 2024 |
Monday, 8 July 2024
|
|
| US Equities Markets End Mixed as Investors Await Inflation Data | |
Monday, 25 September 2023
|
|
| The Surprise That Prompted Morphic Therapeutic To Dump 52% Over Two Days | |
Sunday, 7 May 2023
|
|
| Insiders Pour Millions Into These 2 ‘Strong Buy’ Stocks — Here’s Why You Might Want to Steer Toward Them Too | |
Wednesday, 15 February 2023
|
|
| Revenue Downgrade: Here's What Analysts Forecast For Morphic Holding, Inc. | |
Thursday, 26 January 2023
|
|
| The Petri Dish: Morphic, J&J part ways; FDA committee to review another Biogen drug | |
Wednesday, 14 April 2021
|
|
| Is Morphic Holding a Buy? | |
Tuesday, 2 March 2021
|
|
| Why Morphic Holding Stock Is Falling Today | |
Wednesday, 9 December 2020
|
|
| Is MORF A Good Stock To Buy Now? | |
Monday, 10 August 2020
|
|
| Morphic Holding, Inc. Reports Q2 Loss, Tops Revenue Estimates | |
Friday, 7 August 2020
|
|
| Morphic Holding's Stock Price Has Reduced13% In The Past Year | |
Saturday, 30 November 2019
|
|
| Hedge Funds Are Dumping Morphic Holding, Inc. | |
Wednesday, 30 October 2019
|
|
| Hedge Funds Have Never Been This Bullish On Morphic Holding, Inc. | |
Monday, 1 July 2019
|
|
| Morphic Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares | |
Thursday, 27 June 2019
|
|
| Biotech Companies Soar in Stock Market Debuts | |
| Morphic Opens Above IPO Price | |
Wednesday, 26 June 2019
|
|
| Morphic Announces Pricing of Upsized Initial Public Offering | |
| Insider |
Trans.
Transaction
|
Total value |
|---|---|---|
| Bruce Rogers President | Option 27 Mar 2024 | $31,968 |
| Praveen P. Tipirneni CEO | Option 12 Jan 2024 | $1,167,180 |
| Marc Schegerin CFO and COO | Option 12 Jan 2024 | $538,153 |
| Bruce Rogers President | Option 12 Jan 2024 | $563,998 |
| Robert E Jr Farrell SVP Finance and CAO | Option 12 Jan 2024 | $448,670 |
| William De Vaul General Counsel and Secretary | Option 12 Jan 2024 | $394,618 |
| Martin Edwards | Buy 13 Nov 2023 | $48,803 |
| Joseph P Slattery | Buy 13 Nov 2023 | $49,440 |
| Marc Schegerin CFO and COO | Option 7 Sep 2023 | $300,000 |
| Praveen P. Tipirneni CEO | Option 1 Aug 2023 | $15,539 |
| Praveen P. Tipirneni CEO | Option 3 Jul 2023 | $15,539 |
Powered by
Robintrack.
| Insider | Age | Since | Compensation |
|---|---|---|---|
| Timothy Springer (71) Founder and Independent Director since 2015 | 71 | 2015 | $1,260,500 |
| Alexey Lugovskoy (47) Chief Development Officer since 2016 | 47 | 2016 | $1,005,180 |
| Dr. Praveen P. Tipirneni M.D. (53) CEO, Pres, and Director | 53 | $936,324 | |
| William DeVaul (49) General Counsel and Secretary since 2019 | 49 | 2019 | $790,245 |
| Praveen Tipirneni (51) President, Chief Executive Officer, and Director since 2015 | 51 | 2015 | $788,231 |
| Dr. Marc Schegerin M.B.A., M.D. (45) CFO and COO | 45 | $597,088 | |
| Bruce Rogers (51) Chief Scientific Officer since 2016 | 51 | 2016 | $528,711 |
| Vikas Goyal (41) Independent Director since 2016 | 41 | 2016 | $377,024 |
| Gustav Christensen (72) Independent Chairman of the Board since 2016 | 72 | 2016 | $292,516 |
| Joseph Slattery (55) Independent Director since 2019 | 55 | 2019 | $262,516 |
| Otello Stampacchia (51) Independent Director since 2018 | 51 | 2018 | $260,016 |
| Norbert Bischofberger | 2019 | $257,516 | |
| Amir Nashat (46) Independent Director since 2017 | 46 | 2017 | $257,016 |
| Dr. Timothy A. Springer Ph.D. (73) Founder, Independent Director, and Member of Scientific Advisory Board | 73 | $35,000 | |
| Nilesh Kumar (43) Independent Director since 2018 | 43 | 2018 | |
| Peter Linde (53) Chief Medical Officer since 2020 | 53 | 2020 | |
| Robert Farrell (54) Senior Vice President - Finance and Chief Accounting Officer since 2020 | 54 | 2020 | |
| Marc Schegerin (44) Chief Financial Officer and Chief Operating Officer since 2020 | 44 | 2020 | |
| Adrian S. Ray Ph.D. | |||
| Blaise Lippa | |||
| William D. DeVaul Esq. (50) Gen. Counsel and Sec. | 50 | ||
| Dr. Bruce N. Rogers (52) Chief Scientific Officer | 52 | ||
| Robert E. Farrell Jr., CPA, CPA (56) Sr. VP of Fin./Operations and Chief Accounting Officer | 56 |
oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. morphic tx is joining a three decade quest led by our scientific founder, tim springer, who initially discovered the integrin receptor family in the 1980s. this receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, crohn's disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention. despite blockbuster commercial success, integrins have remained out of reach as small molecule drugs...until now.
- Health Care > Biotechnology
- Morphic Holding Inc, 35 Gatehouse Drive, A2, Waltham 02451, United States
- 781 996 0955
- Investor relations
Quarterly EPS estimates
Profit margin
Debt to assets
Cash flow
Balance sheet
XSLX
| (in millions USD) | 31 Mar 2024 | 31 Dec 2023 | |||
|---|---|---|---|---|---|
| Current assets | |||||
| Cash | $45.026 | $59.137 | |||
| Short term investments | $614.356 | $645.772 | |||
| Net receivables | |||||
| Inventory | |||||
| Total current assets | $675.941 | $716.928 | |||
| Long term investments | |||||
| Property, plant & equipment | $5.851 | $4.9 | |||
| Goodwill & intangible assets | |||||
| Total noncurrent assets | $6.824 | $5.586 | |||
| Total investments | $614.356 | $645.772 | |||
| Total assets | $682.765 | $722.514 | |||
| Current liabilities | |||||
| Accounts payable | $5.748 | $7.698 | |||
| Deferred revenue | |||||
| Short long term debt | |||||
| Total current liabilities | $17.711 | $24.776 | |||
| Long term debt | $1.474 | $0.716 | |||
| Total noncurrent liabilities | $1.474 | $0.716 | |||
| Total debt | $1.474 | $0.716 | |||
| Total liabilities | $19.185 | $25.492 | |||
| Stockholders' equity | |||||
| Retained earnings | -$494.484 | -$449.19 | |||
| Other stockholder equity | -$0.231 | $2.288 | |||
| Total stockholder equity | $663.58 | $697.022 | |||
| (in millions USD) | 2023 | 2022 | ||
|---|---|---|---|---|
| Current assets | ||||
| Cash | $59.137 | $59.832 | ||
| Short term investments | $645.772 | $288.976 | ||
| Net receivables | $0.455 | |||
| Inventory | ||||
| Total current assets | $716.928 | $362.182 | ||
| Long term investments | ||||
| Property, plant & equipment | $4.9 | $5.633 | ||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $5.586 | $6.407 | ||
| Total investments | $645.772 | $288.976 | ||
| Total assets | $722.514 | $368.589 | ||
| Current liabilities | ||||
| Accounts payable | $7.698 | $3.475 | ||
| Deferred revenue | $0.47 | |||
| Short long term debt | ||||
| Total current liabilities | $24.776 | $17.126 | ||
| Long term debt | $0.716 | $2.344 | ||
| Total noncurrent liabilities | $0.716 | $2.344 | ||
| Total debt | $0.716 | $2.344 | ||
| Total liabilities | $25.492 | $19.47 | ||
| Stockholders' equity | ||||
| Retained earnings | -$449.19 | -$297.095 | ||
| Other stockholder equity | $2.288 | -$3.339 | ||
| Total stockholder equity | $697.022 | $349.119 | ||
Income statement
| (in millions USD) | 31 Mar 2024 | 31 Dec 2023 | |||
|---|---|---|---|---|---|
| Revenue | |||||
| Total revenue | |||||
| Cost of revenue | |||||
| Gross profit | |||||
| Operating activities | |||||
| Research & development | $42.441 | $39.852 | |||
| Selling, general & administrative | $11.163 | $9.579 | |||
| Total operating expenses | $53.604 | $49.431 | |||
| Operating income | -$53.604 | -$49.431 | |||
| Income from continuing operations | |||||
| EBIT | -$45.214 | -$40.608 | |||
| Income tax expense | $0.08 | $0.127 | |||
| Interest expense | |||||
| Net income | |||||
| Net income | -$45.294 | -$40.735 | |||
| Income (for common shares) | -$45.294 | -$40.735 | |||
| (in millions USD) | 2023 | 2022 | ||
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.521 | $70.808 | ||
| Cost of revenue | ||||
| Gross profit | $0.521 | $70.808 | ||
| Operating activities | ||||
| Research & development | $140.384 | $102.062 | ||
| Selling, general & administrative | $38.823 | $32.142 | ||
| Total operating expenses | $179.207 | $134.204 | ||
| Operating income | -$178.686 | -$63.396 | ||
| Income from continuing operations | ||||
| EBIT | -$151.715 | -$58.974 | ||
| Income tax expense | $0.38 | $0.067 | ||
| Interest expense | ||||
| Net income | ||||
| Net income | -$152.095 | -$59.041 | ||
| Income (for common shares) | -$152.095 | -$59.041 | ||
Cash flows
| (in millions USD) | 31 Mar 2024 | 31 Dec 2023 | |||
|---|---|---|---|---|---|
| Net income | -$45.294 | -$40.735 | |||
| Operating activities | |||||
| Depreciation | $0.282 | $0.28 | |||
| Business acquisitions & disposals | |||||
| Stock-based compensation | $13.375 | $10.518 | |||
| Total cash flows from operations | -$46.389 | -$28.574 | |||
| Investing activities | |||||
| Capital expenditures | -$0.674 | -$0.093 | |||
| Investments | $32.041 | $12.978 | |||
| Total cash flows from investing | $31.367 | $12.885 | |||
| Financing activities | |||||
| Dividends paid | |||||
| Sale and purchase of stock | $0.911 | $0.034 | |||
| Net borrowings | |||||
| Total cash flows from financing | $0.911 | $0.034 | |||
| Effect of exchange rate | |||||
| Change in cash and equivalents | -$14.111 | -$15.655 | |||
| (in millions USD) | 2023 | 2022 | ||
|---|---|---|---|---|
| Net income | -$152.095 | -$59.041 | ||
| Operating activities | ||||
| Depreciation | $1.091 | $1.005 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | $40.943 | $29.048 | ||
| Total cash flows from operations | -$112.312 | -$100.977 | ||
| Investing activities | ||||
| Capital expenditures | -$1.241 | -$0.365 | ||
| Investments | -$340.574 | -$56.086 | ||
| Total cash flows from investing | -$341.815 | -$56.451 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $453.432 | $45.266 | ||
| Net borrowings | ||||
| Total cash flows from financing | $453.432 | $45.266 | ||
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$0.695 | -$112.162 | ||
Recent institutional transactions
| Quarter | Shareholder | Change |
Shares owned
Shares
|
Value (in thousands USD) |
|---|---|---|---|---|
| 2024 Q2 | Dnb Asset Management As |
+9.32%
|
7,202 | $245,300 |
| 2024 Q1 | Bnp Paribas Financial Markets |
-46.78%
|
47,021 | $1,655,139 |
| 2024 Q1 | Marshall Wace, LL.P. |
-44.21%
|
48,987 | $1,724,343 |
| 2024 Q1 | E Fund Management Co |
Opened
|
10,434 | $367,277 |
| 2024 Q1 | China Universal Asset Management Co |
+2,356.63%
|
9,630 | $338,976 |
| 2024 Q1 | Ubs Asset Management Americas |
+66.31%
|
19,881 | $699,811 |
| 2024 Q1 | Bank Of New York Mellon Corp |
-3.66%
|
124,894 | $4,396,268 |
| 2024 Q1 | Amalgamated Bank |
-75.38%
|
1,254 | $44 |
| 2024 Q1 | Teachers Retirement System Of The State Of Kentucky |
+14.82%
|
17,167 | $604 |
| 2024 Q1 | Pacer Advisors |
Opened
|
1,030 | $36,256 |
Institutional shareholders
| Shareholder | Stake |
Shares owned
Shares
|
Value (in thousands USD) |
|---|---|---|---|
| Geode Capital Management | 1.70% | 853,040 | |
| Silverarc Capital Management | 1.18% | 590,829 | |
| Marshall Wace North America L.P. | 1.16% | 579,537 | |
| Finepoint Capital L.P. | 0.99% | 496,856 | |
| Omega Fund Management | 0.62% | 309,846 | |
| Dafna Capital Management | 0.46% | 231,748 | |
| Baker Bros. Advisors L.P. | 0.43% | 215,800 | |
| Driehaus Capital Management | 0.27% | 136,465 | |
| Fred Alger Management | 0.26% | 132,745 | |
| Bank Of New York Mellon Corp | 0.25% | 124,894 |
Sign up